🔎 Trials Near Me

Home › Cancro ai polmoni › Michigan

Studi clinici su Cancro ai polmoni nello stato di Michigan

44 studi su Cancro ai polmoni cercano partecipanti presso sedi nello stato di Michigan.

Città nello stato di Michigan

Testo ufficiale dello studio (inglese)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Bronson Battle Creek, Battle Creek
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • e altri 50
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04267848

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • e altri 68
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  • Bronson Battle Creek, Battle Creek
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • e altri 20
In reclutamentoFase 3
Età 70 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • e altri 27
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT04181060

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • University of Michigan Rogel Cancer Center, Ann Arbor
  • Bronson Battle Creek, Battle Creek
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • e altri 38
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06498635

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Trinity Health Ann Arbor Hospital, Ann Arbor
  • Karmanos Cancer Institute, Detroit
  • Henry Ford Health, Detroit
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06881784

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Corewell Health - Butterworth Hospital, Grand Rapids
  • Corewell Health - Lemmen Holton Cancer Pavilion, Grand Rapids
  • Corewell Health - Research Specimen Processing Area, Grand Rapids
  • e altri 2
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06758401

A Registry for People With Lung Cancer

  • University of Michigan (Data Collection Only), Ann Arbor
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06424327

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  • Local Institution - 0418, Ann Arbor
  • Local Institution - 0405, Detroit
  • Local Institution - 0420, Traverse City
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07063745

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • START Midwest, Grand Rapids
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06128551

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

  • University of Michigan Medical School Rogel Cancer Center, Ann Arbor
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07629960

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

  • START Midwest, Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07349537

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT05786924

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Karmanos Cancer Institiute, Detroit
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • University of Michigan, Ann Arbor
  • The Cancer & Hematology Centers, Grand Rapids
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06119581

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06400472

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  • Henry Ford Cancer - Detroit, Detroit
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06343402

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Henry Ford Cancer Institute-Downriver, Brownstown
  • Henry Ford Health Center - Brownstown, Brownstown
  • Henry Ford Health Center - Chesterfield, Chesterfield
  • e altri 13
In reclutamentoVolontari sani benvenuti
Età da 45 a 75 · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06995898

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

  • University of Michigan, Ann Arbor
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT07499674

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  • Wayne State University/Karmanos Cancer Institute, Detroit
  • Weisberg Cancer Treatment Center, Farmington Hills
  • McLaren Cancer Institute-Flint, Flint
  • e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT06500481

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • McLaren Cancer Institute-Bay City, Bay City
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • e altri 41
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05624996

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • Karmanos Cancer Institute, Detroit
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT05592626

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • START - Midwest, Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT07444814

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Henry Ford Cancer Institute, Detroit
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 lug 2026 · NCT04198766

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

  • Henry Ford Cancer- Detroit, Detroit
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 lug 2026 · NCT07339059

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 giu 2026 · NCT06162221

Gilteritinib for the Treatment of ALK NSCLC

  • University of Michigan Comprehensive Cancer Center, Ann Arbor
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 26 giu 2026 · NCT06225427

Prediction Augmented Screening Initiative

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
In reclutamento
Età da 50 a 80 · Tutti i sessi · Aggiornato il 26 giu 2026 · NCT06538636

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • Karmanos Cancer Institute, Detroit
In reclutamentoFase 2
Età da 18 a 70 · Tutti i sessi · Aggiornato il 26 giu 2026 · NCT04614103

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • e altri 19
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 giu 2026 · NCT05642572

A Study of ZW251 in Participants With Advanced Solid Tumors

  • START Midwest, Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 mag 2026 · NCT07164313

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • e altri 14
In reclutamentoFase 2
18 Minutes · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
  • e altri 7
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT06616584

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  • University of Michigan, Ann Arbor
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 apr 2026 · NCT07020221

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  • Karmanos Cancer Institute, Detroit
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 mar 2026 · NCT06244771

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 feb 2026 · NCT02984761

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 27 gen 2026 · NCT05467748

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

  • University of Michigan Comprehensive Cancer Center, Ann Arbor
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 gen 2026 · NCT07291414

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.